Evidence map›Paper›PMID 31488111›Full record

ArticleBMC complementary and alternative medicine2019

The protective effect and mechanism of catalpol on high glucose-induced podocyte injury.

Yan Chen, Qingpu Liu, Zengfu Shan, Yingying Zhao, Meng Li, Baiyan Wang, Xiaoke Zheng, Weisheng Feng

Open access · goldAbstract read
In one paragraph

Article in BMC complementary and alternative medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Chemical Constituents from the Flowers ofMolecules (Basel, Switzerland) · 2022
    Article
  9. Pharmaceuticals (Basel, Switzerland) · 2022
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yan ChenCollege of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, People's Republic of China.
Qingpu LiuCollege of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, People's Republic of China.
Zengfu ShanCollege of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, People's Republic of China.
Yingying ZhaoCollege of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, People's Republic of China.
Meng LiCollege of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, People's Republic of China.
Baiyan WangCollege of Basic Medicine, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, People's Republic of China.
Xiaoke ZhengCollege of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, People's Republic of China. zhengxk.2006@163.com.
Weisheng FengCollege of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, People's Republic of China. fwsh@hactcm.edu.cn.
First Affiliated Hospital of Henan University · CN

Funding

The Major Science and Technology Projects in Henan Province: Study on the key technology for quality control and the key characteristics of Rehmannia glutinosa, Dioscorea opposita Thunb and Achyranthes bidentata Blume from Henan Province 171100310500The National Key Research and Development Project (The Major Project for Research of the Modernization of TCM): Key Technology Research for the Characteristic Chinese Medicine Industry Chain of Rehmannia glutinosa 2017YFC1702800
6 · The paper itself

Abstract

backgroundCatalpol, a natural iridoid glycoside in Rehmannia glutinosa, can alleviate proteinuria associated with diabetic nephropathy (DN), however, whether catalpol has a protective effect against podocyte injury in DN remains unclear.

methodsIn this study, we used a high glucose (HG)-induced podocyte injury model to evaluate the protective effect and mechanism of catalpol against HG-induced podocyte injury. Cell viability was determined by the 3-(4,5-dimethylthiazolyl-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. The levels of lactate dehydrogenase (LDH), superoxide dismutase (SOD) and malondialdehyde (MDA) were measured by commercial assay kits. Cell apoptosis and reactive oxygen species (ROS) were determined by using flow cytometry. Tumour necrosis factor α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) levels were determined by enzyme-linked immunosorbent assay (ELISA). The protein expression levels of B-cell lymphoma-2 (Bcl-2), Bcl2-associated x (Bax), cleaved caspase-3, nicotinamide adenine dinucleotide phosphate oxidase enzyme 4 (NOX4), toll-like receptor 4 (TLR4), myeloid differentiation primary response gene 88 (MyD88), p38 mitogen-activated protein kinase (p38 MAPK), phosphorylated p38 MAPK (p-p38 MAPK), nuclear factor kappa B inhibitor alpha (IκBα) and phosphorylated IκBα (p-IκBα) were measured by western blotting. In addition, Bcl-2, Bax, caspase-3 and nuclear factor kappa B (NF-κB) levels were determined by immunofluorescence staining.

resultsCatalpol significantly increased cell viability and decreased LDH release in HG-induced podocyte injury. Catalpol significantly decreased ROS generation, apoptosis, level of MDA, levels of inflammatory cytokine TNF-α, IL-1β, and IL-6 and increased SOD activity in HG-induced podocyte injury. Moreover, catalpol significantly decreased expression of cleaved caspase-3, Bax, NOX4, TLR4, MyD88, p-p38 MAPK, p-IκBα and NF-κB nuclear translocation, as well as increased Bcl-2 expression in HG-induced podocyte injury.

conclusionCatalpol can protect against podocyte injury by ameliorating apoptosis and inflammation. These protective effects may be attributed to the inhibition of NOX4, which alleviates ROS generation and suppression of the TLR4/MyD88 and p38 MAPK signaling pathways to prevent NF-κB activation. Therefore, catalpol could be a promising drug for the prevention of DN.

Indexed as

AnimalsApoptosisCell LineDrugs, Chinese HerbalGlucoseInterleukin-6Iridoid GlucosidesMiceNF-kappa BPodocytesProtective AgentsReactive Oxygen SpeciesRehmanniaTumor Necrosis Factor-alphacatalpolDrugs, Chinese HerbalGlucoseInterleukin-6Iridoid GlucosidesNF-kappa BProtective AgentsReactive Oxygen SpeciesTumor Necrosis Factor-alphaCatalpolDiabetic nephropathyMechanismPodocyte injuryRehmannia glutinosa

Identifiers

PMID31488111
PMCPMC6727542
OpenAlexW2972233352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.